Clinical Trials
42 trialsOMAHA-003
Merck Sharp & Dohme LLC
GETUG-AFU 40
UNICANCER
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
ANCHORProstate
Centre hospitalier de l'Université de Montréal (CHUM)
PLATON
Canadian Cancer Trials Group
METRO
Umeå University
STAMPEDE2
University College, London
CYPIDES
Orion Corporation, Orion Pharma
FTT PET/CT in Metastatic Prostate Cancer
Abramson Cancer Center at Penn Medicine
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CRPC
DexTech Medical AB
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc.
PEAPOD_FOS
Fundacion Oncosur
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Fudan University
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fortis Therapeutics, Inc.
ACTION
Weill Medical College of Cornell University
ROTOR
The Netherlands Cancer Institute
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
Peking Union Medical College Hospital
IMANOL
Spanish Oncology Genito-Urinary Group
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC
University Hospital Virgen de las Nieves
CARD
Sanofi
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Veru Inc.
iPROMET
Vall d'Hebron Institute of Oncology
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
University of Hawaii
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
West China Hospital
Telaglenastat + Talazoparib In Prostate Cancer
Massachusetts General Hospital
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Oligomet_DK
Herlev Hospital
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Rigshospitalet, Denmark
PRIMCAB
Sanofi
Post-eRADicAte
Carolina Research Professionals, LLC
TAXYNERGY
Sanofi
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
DexTech Medical AB
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
PERSEUS
EMD Serono
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
DexTech Medical AB